Unresectable GIST liver metastases and liver transplantation: A review and theoretical basis for a new indication.

Szczegóły
Abstrakt

Tytuł:: Unresectable GIST liver metastases and liver transplantation: A review and theoretical basis for a new indication.
Autorzy:: Fernández JÁ; Department of Surgery and Organ Transplantation. Virgen de la Arrixaca University Hospital. Ctra. Madrid-Cartagena s/n, 30120 Murcia Spain Department of Clinical Oncology. Virgen de la Arrixaca University Hospital. Ctra. Madrid-Cartagena s/n, 30120 Murcia Spain Biomedical Research Institute of Murcia (IMIB-Arrixaca). Campus de Ciencias de la Salud. Ctra. Buenavista s/n, 30120 Murcia Spain.
Alconchel F
Gómez B
Martínez J
Ramírez P
Źródło:: International journal of surgery (London, England) [Int J Surg] 2021 Oct; Vol. 94, pp. 106126. Date of Electronic Publication: 2021 Sep 27.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Publication: 2023- : [Philadelphia] : Wolters Kluwer Health, Inc.
Original Publication: London : Surgical Associates Ltd., c2004-
MeSH Terms:: Antineoplastic Agents*/therapeutic use
Gastrointestinal Stromal Tumors*/drug therapy
Gastrointestinal Stromal Tumors*/surgery
Liver Neoplasms*/drug therapy
Liver Neoplasms*/surgery
Liver Transplantation*
Humans ; Imatinib Mesylate/therapeutic use ; Prospective Studies
References:: Tarn C, Godwin AK. The Molecular Pathogenesis of Gastrointestinal Stromal Tumors. Clin Colorectal Cancer [Internet]. 2006 [cited 2020 Dec 8];6 Suppl 1. Available from https://pubmed.ncbi.nlm.nih.gov/17101067/.
Mazur MT, Clark HB. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol [Internet] 1983. [cited 2020 Dec 8];7(6):507–19. Available from: https://pubmed.ncbi.nlm.nih.gov/6625048/.
Von Mehren M, Randall RL, Benjamin RS, Boles S, Bui MM, Casper ES, et al. Gastrointestinal Stromal Tumors, Version 2.2014: Featured Updates to the NCCN Guidelines. [Internet], 2014 Jun 1, JNCCN J Natl Compr Cancer Netw, [cited 2020 Dec 8];12(6):853–62. Available from: https://pubmed.ncbi.nlm.nih.gov/24925196/.
Rm T, Lh S. Gastrointestinal cancer. Cancer [Internet]. 1995 [cited 2020 Dec 8];75(1 Suppl). Available from: https://pubmed.ncbi.nlm.nih.gov/8000994/.
Fletcher CDM, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of Gastrointestinal Stromal Tumors: A Consensus Approach. Hum Pathol [Internet], 2002, [cited 2020 Dec 8];33(5):459–65. Available from: https://pubmed.ncbi.nlm.nih.gov/12094370/.
Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours [Internet]. Journal of Clinical Pathology. vol. 59, 2006, J Clin Pathol, cited 2020 Dec 8]. pp. 557–63. Available from: https://pubmed.ncbi.nlm.nih.gov/16731599/.
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. [Internet] Science (80- ) 1998 Jan 23. [cited 2020 Dec 8];279(5350):577–80. Available from. https://pubmed.ncbi.nlm.nih.gov/9438854/.
Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors [Internet]. Journal of Clinical Oncology. vol. 22, 2004, J Clin Oncol, [cited 2020 Dec 8]. pp. 3813–25. Available from: https://pubmed.ncbi.nlm.nih.gov/15365079/.
Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis [Internet]. Vol. 130, Archives of Pathology and Laboratory Medicine. 2006, Arch Pathol Lab Med, cited 2020 Dec 8]. pp. 1466–78. Available from: https://pubmed.ncbi.nlm.nih.gov/17090188/.
Kim BJ, Milgrom DP, Feizpour C, Kays JK, Koniaris LG. Role for targeted resection in the multidisciplinary treatment of metastatic gastrointestinal stromal tumor [Internet]. Translational Gastroenterology and Hepatology. vol. 4, 2019, AME Publishing Company, [cited 2020 Dec 8]. Available from: https://pubmed.ncbi.nlm.nih.gov/31143847/.
Gleevec FDA. (imatinib mesylate). Techical brochure [Internet]. [cited 2020 Dec 8]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/21335lbl.pdf.
Gold JS, DeMatteo RP. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model [Internet]. Annals of Surgery. Ann Surg. 244, 2006, [cited 2020 Dec 8]. pp. 176–84. Available from: https://pubmed.ncbi.nlm.nih.gov/16858179/.
DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two Hundred Gastrointestinal Stromal Tumors: Recurrence Patterns and Prognostic Factors for Survival. Ann Surg [Internet], 2000 Jan, [cited 2020 Dec 8];231(1):51–8. Available from https://pubmed.ncbi.nlm.nih.gov/10636102/.
Ng EH, Pollock RE, Munsell MF, Atkinson EN, Romsdahl MM. Prognostic Factors Influencing Survival in Gastrointestinal Leiomyosarcomas: Implications for Surgical Management and Staging. Ann Surg [Internet], 1992, [cited 2020 Dec 8];215(1):68–77. Available from: https://pubmed.ncbi.nlm.nih.gov/1731651/.
Ng E.-H, Pollock RE, Romsdahl MM. Prognostic Implications of Patterns of Failure for Gastrointestinal Leiomyosarcomas. Cancer [Internet], 1992, [cited 2020 Dec 8];69(6):1334–41. Available from: https://pubmed.ncbi.nlm.nih.gov/1540870/.
Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, et al. Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. [Internet], Annals of Oncology. 2005, Ann Oncol, [cited 2020 Dec 8]. pp. 566–78. Available from: https://pubmed.ncbi.nlm.nih.gov/15781488/.
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet [Internet], [cited 2020 Dec 8];364(9440):1127–34. Available from https://pubmed.ncbi.nlm.nih.gov/15451219/ 2004 Sep 25.
Van Der Zwan SM, DeMatteo RP. Gastrointestinal Stromal Tumor: 5 Years Later [Internet]. vol. 104, 2005, Cancer. Cancer, [cited 2020 Dec 8]. pp. 1781–8. Available from: https://pubmed.ncbi.nlm.nih.gov/16136600/.
Blanke CD, Demetri GD, Von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J. Clin. Oncol. 2008 Feb 1. [cited 2020 Dec 8];26(4):620–5. Available from: https://pubmed.ncbi.nlm.nih.gov/18235121/ . [Internet].
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet [Internet], [cited 2020 Dec 8];368(9544):1329–38. Available from: https://pubmed.ncbi.nlm.nih.gov/17046465/ 2006 Oct 14.
Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. [Internet] J. Clin. Oncol. 2006 May 20. [cited 2020 Dec 8];24(15):2325–31. Available from: https://pubmed.ncbi.nlm.nih.gov/16710031/.
Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, et al. Surgery of Residual Disease Following Molecular-Targeted Therapy with Imatinib Mesylate in Advanced/metastatic GIST. Ann Surg [Internet], 2007, Mar [cited 2020 Dec 8];245(3):341–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17435538/.
Mussi C, Ronellenfitsch U, Jakob J, Tamborini E, Reichardt P, Casali PG, et al. Post-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients? Ann Oncol [Internet], [cited 2020 Dec 8];21(2):403–8. Available from https://pubmed.ncbi.nlm.nih.gov/19628568/ 2010 Feb.
Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, et al. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated with Tyrosine Kinase Inhibitors: A 2-institutional Analysis. Ann Surg [Internet], 2018 Aug 1, [cited 2020 Dec 8];268(2):296–302. Available from: https://pubmed.ncbi.nlm.nih.gov/28448384/.
DeMatteo RP, Maki RG, Singer S, Gonen M, Brennan MF, Antonescu CR. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 2007. Mar [cited 2020 Dec 8];245(3):347–52. Available from: https://pubmed.ncbi.nlm.nih.gov/17435539/ . [Internet].
Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, et al. Transplant Oncology in Primary and Metastatic Liver Tumor: Principles, Evidence and Opportunities. Ann Surg [Internet], 2020 Oct 15, Available from: http://www.ncbi.nlm.nih.gov/pubmed/33065633.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar 29;372:n71. doi: 10.1136/bmj.n71. PMID: 33782057; PMCID: PMC8005924.
Wohlin C. Guidelines for snowballing in systematic literature studies and a replication in software engineering. ACM International Conference Proceeding Series. 2014, Association for Computing Machinery.
Wenjing W, Xiaofeng Z, Anbin H, Qing C. Liver transplantation for liver metastasis of gastrointestinal stromal tumor. J Abdom Surg [Internet. 32(3): 2019, 206-211, Available from: http://www.fbwk.net/EN/abstract/abstract292.shtml#.
Benítez C, Inzunza M, Riveros S, Rivas V, Garrido M, Dib M, et al. Living Donor Liver Transplantation for Imatinib-Resistant Gastrointestinal Stromal Tumor Liver Metastases: A New Therapeutic Option in Transplant Oncology. Liver Transplant [Internet], 2020 Jul 1, [cited 2020 Dec 8];26(7):945–8. Available from: https://pubmed.ncbi.nlm.nih.gov/32246733/.
Iesari S, Mocchegiani F, Nicolini D, Benedetti Cacciaguerra A, Coletta M, Montalti R, et al. Liver Transplantation for Metastatic Wild-type Gastrointestinal Stromal Tumor in the Era of Molecular Targeted Therapies: Report of a First Case. Am J Transplant [Internet] 2019 Oct 1, [cited 2020 Dec 8];19(10):2939–43. Available from: https://pubmed.ncbi.nlm.nih.gov/30943317/.
W. L, A. H, X. Z. Liver transplantation for a metastasized duodenal gastrointestinal stromal tumor: a case report and review of the literature. Int. J. Clin. Exp. Med. 2019. [cited 2020 Dec 8];12(5):5419–25. Available from: www.ijcem.com/ . [Internet].
Mocchegiani F, Iesari S, Nicolini D, Coletta M, Conte G, Dalla Bona E, et al. Liver transplantation for metastatic pediatric GIST: first case of a two-stage surgical approach. Association [Internet], HPB 13th World Congress of the International Hepato-Pancreato-Biliary. 2018, Elsevier BV, [cited 2020 Dec 8]. p. S786–7. Available from: http://www.hpbonline.org/article/S1365182X18337572/fulltext.
Frilling A, Malago M, Testa G, Schleyer E, Grabellus F, Kronenberger R, et al. Liver transplantation for metastasized extragastrointestinal stromal tumor: a case report and an overview of literature. Transplant Proc [Internet] 2010 Nov. [cited 2020 Dec 8];42(9):3843–8. Available from. https://pubmed.ncbi.nlm.nih.gov/21094867/.
Stauffer JA, Steers JL, Bonatti H, Dougherty MK, Aranda-Michel J, Dickson RC, et al. Liver Transplantation and Pancreatic Resection: A Single-Center Experience and a Review of the Literature. Liver Transplant [Internet], 2009 Dec, [cited 2020 Dec 8];15(12):1728–37. Available from https://pubmed.ncbi.nlm.nih.gov/19938125/.
Dougherty M, Bonatti H, Dickson RC, Aranda-Michel J, Hinder R, Nguyen J, et al. Management of metastatic gastrointestinal stromal tumor by multiple surgical interventions including pancreatoduodenectomy, liver resection and two liver transplants: worth the effort? Eur Surg - Acta Chir Austriaca [Internet] 2007. [cited 2020 Dec 8];39(3):189–91. Available from: https://link.springer.com/article/10.1007/s10353-007-0327-3.
Cameron S, Ramadori G, Füzesi L, Sattler B, Gunawan B, Müller D, et al. [2] [Internet], Successful Liver Transplantation in Two Cases of Metastatic Gastrointestinal Stromal Tumors. vol. 80, 2005, Transplantation. Transplantation, [cited 2020 Dec 8]. pp. 283–4. Available from: https://pubmed.ncbi.nlm.nih.gov/16041278/.
Serralta AS, Sanjuan FR, Moya AH, Obis FC, López-Andújar R, Pareja EI, et al. Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours. Eur J Gastroenterol Hepatol [Internet]. 16(11): 2004 Nov, 1237-1239, [cited 2020 Dec 8] https://pubmed.ncbi.nlm.nih.gov/15489588/ . Available from.
Bompas E, Boillot O, Bringuier PP, Dumortier J, Blay JY. [3] [Internet], Imatinib Mesylate in Patients with Metastatic Gastrointestinal Stromal Tumour Relapsing after Hepatic Transplantation. vol. 40, 2004, European Journal of Cancer. Eur J Cancer, [cited 2020 Dec 8]. pp. 1456–7. Available from: https://pubmed.ncbi.nlm.nih.gov/15177508/.
Husted TL, Neff G, Thomas MJ, Gross TG, Woodle ES, Buell JF. Liver Transplantation for Primary or Metastatic Sarcoma to the Liver. Am J Transplant [Internet], [cited 2020 Dec 8];6(2):392–7. Available from: https://pubmed.ncbi.nlm.nih.gov/16426326/ 2006 Feb.
Oishi K, Itamoto T, Kobayashi T, Oshita A, Amano H, Ohdan H, et al. Hepatectomy for hepatocellular carcinoma in elderly patients aged 75 years or more. J. Gastrointest. Surg . 2009;13(4):695-701.
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. [Internet] N. Engl. J. Med. 2001 Apr 5. [cited 2020 Dec 8];344(14):1052–6. Available from: https://pubmed.ncbi.nlm.nih.gov/11287975/.
von Mehren M, Heinrich MC, Joensuu H, Blanke CD, Wehrle E, Demetri GD. Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST). Journal of Clinical Oncology. 2011, American Society of Clinical Oncology (ASCO), 10016–10016.
Heinrich MC, Rankin C, Blanke CD, Demetri GD, Borden EC, Ryan CW, et al. Correlation of long-term results of imatinib in advanced gastrointestinal stromal tumors with next-generation sequencing results: analysis of phase 3 SWOG intergroup trial S0033. JAMA Oncol [Internet], [cited 2020 Dec 8];3(7):944–52. Available from: https://pubmed.ncbi.nlm.nih.gov/28196207/ 2017 Jul 1.
Casali PG, Fumagalli E, Gronchi A, Zalcberg J, Kotasek D, Cesne A Le, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic GI stromal tumors: long-term analysis of the european organisation for research and treatment of cancer, Italian sarcoma group, and Australasian gastrointestinal trials group intergroup phase III randomized trial on imatinib at two dose levels. [Internet] J. Clin. Oncol. 2017 May 20. [cited 2020 Dec 8];35(15):1713–20. Available from: https://pubmed.ncbi.nlm.nih.gov/28362562/.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Effi Cacy and Safety of Regorafenib for Advanced Gastrointestinal Stromal Tumours after Failure of Imatinib and Sunitinib (GRID): an International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. Lancet [Internet], 2013, [cited 2020 Dec 8];381(9863):295–302. Available from: https://pubmed.ncbi.nlm.nih.gov/23177515/.
Kim JH, Ryu MH, Yoo C, Chae H, Na H, Beck M, et al. Long-term Survival Outcome with Tyrosine Kinase Inhibitors and Surgical Intervention in Patients with Metastatic or Recurrent Gastrointestinal Stromal Tumors: A 14-year, Single-Center Experience. Cancer Med [Internet], 2019 Mar 1, [cited 2020 Dec 8];8(3):1034–43. Available from https://pubmed.ncbi.nlm.nih.gov/30693663/.
Ford SJ, Gronchi A. Indications for surgery in advanced/metastatic GIST. [Internet] European Journal of Cancer. Elsevier Ltd. 63, 2016, [cited 2020 Dec 8]. pp. 154–67. Available from: https://pubmed.ncbi.nlm.nih.gov/27318456/.
Bauer S, Hartmann JT, Lang H, Antoch G, Dirsch O, Ebeling P, et al. Imatinib may enable complete resection in previously unresectable or metastatic GIST. Journal of Clinical Oncology. 2004, American Society of Clinical Oncology (ASCO), 9023–9023.
Bümming P, Andersson J, Meis-Kindblom JM, Klingenstierna H, Engström K, Stierner U, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer [Internet] 2003 Aug 4. [cited 2020 Dec 8];89(3):460–4. Available from. https://pubmed.ncbi.nlm.nih.gov/12888812/.
Scaife CL, Hunt KK, Patel SR, Benjamin RS, Burgess MA, Chen LL, et al. Is there a role for surgery in patients with “unresectable” cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? [Internet] Am. J. Surg. 2003. [cited 2020 Dec 8];186(6):665–9. Available from: https://pubmed.ncbi.nlm.nih.gov/14672776/.
Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, et al. Is There a Role of Surgery in Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumours Responding to Imatinib: A Prospective Randomised Trial in China. Eur J Cancer [Internet], 2014, [cited 2020 Dec 8];50(10):1772–8. Available from: https://pubmed.ncbi.nlm.nih.gov/24768330/.
Bonvalot S, Eldweny H, Péchoux C Le, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol [Internet] 2006 Dec. [cited 2020 Dec 8];13(12):1596–603. Available from. https://pubmed.ncbi.nlm.nih.gov/16957966/.
Andtbacka RHI, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PWT, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol [Internet] 2007 Jan. [cited 2020 Dec 8];14(1):14–24. Available from. https://pubmed.ncbi.nlm.nih.gov/17072676/.
Bui BN, Le Cesne A, Ray-Coquard I, Duffaud F, Rios M, Adenis A, et al. Do patients with initially resected metastatic GIST benefit from ‘adjuvant‘ imatinib (IM) treatment? Results of the prospective BFR14 French Sarcoma Group randomized phase III trial. Journal of Clinical Oncology. 2006, American Society of Clinical Oncology (ASCO), 9501–9501.
Rutkowski P, Nowecki Z, Nyckowski P, Dziewirski W, Grzesiakowska U, Nasierowska-Guttmejer A, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Histotechnol [Internet] 2006 Mar 15. [cited 2020 Dec 8];28(4):304–11. Available from: https://pubmed.ncbi.nlm.nih.gov/16496358/.
Bauer S, Hartmann JT, De Wit M, Lang H, Grabellus F, Antoch G, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer [Internet] 2005 Nov 1. [cited 2020 Dec 8];117(2):316–25. Available from: https://pubmed.ncbi.nlm.nih.gov/15900603/.
Ecker BL, Maki RG, Cavnar MJ, DeMatteo RP. Surgical management of sarcoma metastatic to liver. Surg. Oncol. Clin . 2021;30:57-67.
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). 2014, Eur J Surg Oncol [Internet, [cited 2020 Dec 8];40(4):412–9. Available from: https://pubmed.ncbi.nlm.nih.gov/24491288/.
Sun JS, Ryu MH, Lee JL, Heung MC, Kim TW, Hee CK, et al. Surgical intervention following imatinib treatment in patients with advanced gastrointestinal stromal tumors (GISTs). J Surg Oncol [Internet] 2008 Jul 1. [cited 2020 Dec 8];98(1):27–33. Available from: https://pubmed.ncbi.nlm.nih.gov/18452195/.
Keung EZ, Raut CP, Rutkowski P. The Landmark Series: Systemic Therapy for Resectable Gastrointestinal Stromal Tumors. Ann Surg Oncol [Internet], 2020 Oct 1, [cited 2020 Dec 8];27(10):3659–71. Available from https://pubmed.ncbi.nlm.nih.gov/32734368/.
Tielen R, Verhoef C, van Coevorden F, Gelderblom H, Sleijfer S, Hartgrink HH, et al. Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile? World J Surg Oncol [Internet], [cited 2020 Dec 8];10. Available from https://pubmed.ncbi.nlm.nih.gov/22703877/ 2012 Jun 15.
Machairas N, Prodromidou A, Molmenti E, Kostakis ID, Sotiropoulos GC. Management of liver metastases from gastrointestinal stromal tumors: where do we stand? [Internet], Journal of Gastrointestinal Oncology. vol. 8, 2017, AME Publishing Company, [cited 2020 Dec 8]. pp. 1100–8. Available from: https://pubmed.ncbi.nlm.nih.gov/29299371/.
Nannini M, Pantaleo MA. Letter to the Editor Concerning “Liver Transplantation for Metastatic Wild-type Gastrointestinal Stromal Tumor in the Era of Molecular 7Jun 17. [cited 2020 Dec 8];20(12). Available from: https://pubmed.ncbi.nlm.nih.gov/32463956/.
Hibi T, Sapisochin G. What is transplant oncology? Surgery [Internet]. 2018. http://dx.doi.org/10.1016/j.surg.2018.10.024 [cited 2020 Jan 20];165:281–5. Available from:.
Zilbert N, Sapisochin G. Time to reconsider liver transplantation for intrahepatic cholangiocarcinoma? Inside Internet. vol. 3, 2018, [cited 2020 Dec 8]. pp. 294–5. Available from: https://pubmed.ncbi.nlm.nih.gov/29644969/ . The Lancet Gastroenterology and Hepatology. Elsevier Ltd.
Heinrich MC, Corless CL, Demetri GD, Blanke CD, Von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. [Internet] J. Clin. Oncol. 2003 Dec 1. [cited 2020 Dec 8];21(23):4342–9. Available from: https://pubmed.ncbi.nlm.nih.gov/14645423/.
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of C-KIT/PDGFRA Mutational Analysis to Predict the Clinical Response to Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours Entered on Phase I and II Studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer [Internet], 2004, Mar [cited 2020 Dec 8];40(5):689–95. Available from: https://pubmed.ncbi.nlm.nih.gov/15010069/.
Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol [Internet] 2007 May 1. [cited 2020 Dec 8];25(13):1760–4. Available from: https://pubmed.ncbi.nlm.nih.gov/17470866/.
Choi H. Response Evaluation of Gastrointestinal Stromal Tumors. Oncologist [Internet], 2008 Apr, [cited 2020 Dec 8];13(S2):4–7. Available from https://pubmed.ncbi.nlm.nih.gov/18434631/.
Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of Clinical and Subclinical Tumour Response Using [18F]- Fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations. Eur J Cancer [Internet], 1999 Dec, [cited 2020 Dec 8];35(13):1773–82. Available from https://pubmed.ncbi.nlm.nih.gov/10673991/.
den Abbeele AD for the GCPSG. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST). Proc Am Soc Clin Oncol [Internet], Available from: https://liferaftgroup.org/wp-content/uploads/2012/07/PET_scan_poster_IM_in_GIST.pdf 2001 362a.
Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, Beal EW, Felekouras E, Vernadakis S, et al. Liver Transplantation in Patients with Liver Metastases from Neuroendocrine Tumors: A Systematic Review. Surg (United States) [Internet], 2017 Sep 1, [cited 2020 Dec 8];162(3):525–36. Available from: https://pubmed.ncbi.nlm.nih.gov/28624178/.
Mazzaferro V, Pulvirenti A, Coppa J. Neuroendocrine tumors metastatic to the liver: how to select patients for liver transplantation? [Internet]. J. Hepatol. 47, 2007, cited 2020 Dec 8]. pp. 460–6. Available from: https://pubmed.ncbi.nlm.nih.gov/17697723/ . J Hepatol.
Liu XS, Mardis ER. Applications of Immunogenomics to Cancer [Internet]. vol. 168, 2017, Cell. Cell Press, cited 2020 Dec 8]. pp. 600–12. Available from: https://pubmed.ncbi.nlm.nih.gov/28187283/.
Valle JW, Lamarca A, Goyal L, Barriuso J, Zhu AX. [Internet], New Horizons for Precision Medicine in Biliary Tract Cancers. vol. 7, 2017, Cancer Discovery. American Association for Cancer Research Inc., [cited 2020 Dec 8]. pp. 943–62. Available from: https://pubmed.ncbi.nlm.nih.gov/28818953/.
Amer A, Wilson CH, Manas DM. Liver transplantation for unresectable malignancies: beyond hepatocellular carcinoma [Internet]. 45, 2019, European Journal of Surgical Oncology. W.B. Saunders Ltd, [cited 2020 Dec 8]. pp. 2268–78. Available from: https://pubmed.ncbi.nlm.nih.gov/31387755/.
Line PD, Ruffolo LI, Toso C, Dueland S, Nadalin S, Hernandez-Alejandro R. Liver transplantation for colorectal liver metastases: what do we need to know? International Journal of Surgery. vol. 82, 2020, Elsevier Ltd, [cited 2020 Dec 8]. pp. 87–92. Available from: https://pubmed.ncbi.nlm.nih.gov/32305529/ . [Internet].
Line PD, Dueland S. Liver transplantation for secondary liver tumours: the difficult balance between survival and recurrence [Internet]. Journal of Hepatology. vol. 73, 2020, Elsevier B.V., [cited 2020 Dec 8]. pp. 1557–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32896581/.
Yeh CN, Chen YY, Tseng JH, Chen JS, Chen TW, Tsai CY, et al. Imatinib Mesylate for Patients with Recurrent or Metastatic Gastrointestinal Stromal Tumors Expressing KIT: A Decade Experience from Taiwan. Transl Oncol [Internet], 2011, [cited 2020 Dec 8];4(6):328–35. Available from: https://pubmed.ncbi.nlm.nih.gov/22190996/.
Hompland I, Bruland ϕ.S, Hφlmebakk T, Poulsen JP, Stoldt S, Hall KS, et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort. Acta Oncol (Madr) [Internet] 2017 Oct 3. [cited 2020 Dec 8];56(10):1317–23. Available from. https://pubmed.ncbi.nlm.nih.gov/28557540/.
Rutkowski P, Andrzejuk J, Bylina E, Osuch C, Świtaj T, Jerzak Vel Dobosz A, et al. What Are the Current Outcomes of Advanced Gastrointestinal Stromal Tumors: Who Are the Long-Term Survivors Treated Initially with Imatinib? Med Oncol [Internet], 2013, [cited 2020 Dec 8];30(4). Available from: https://pubmed.ncbi.nlm.nih.gov/24217870/.
Sφreide K, Sandvik OM, Sφreide JA, Giljaca V, Jureckova A, Bulusu VR. [Internet], Global Epidemiology of Gastrointestinal Stromal Tumours (GIST): A Systematic Review of Population-Based Cohort Studies. vol. 40, 2016, Cancer Epidemiology. Elsevier Ltd, cited 2020 Dec 8]. pp. 39–46. Available from: https://pubmed.ncbi.nlm.nih.gov/26618334/.
Khoo CY, Chai X, Quek R, Teo MCC, Goh BKP. Systematic review of current prognostication systems for primary gastrointestinal stromal tumors [Internet]. 44, 2018, European Journal of Surgical Oncology. W.B. Saunders Ltd, [cited 2020 Dec 8]. pp. 388–94. Available from: https://pubmed.ncbi.nlm.nih.gov/29422251/.
Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, et al. Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts. Lancet Oncol 2012. Mar [cited 2020 Dec 8];13(3):265–74. Available from: https://pubmed.ncbi.nlm.nih.gov/22153892/ . [Internet].
Pantaleo MA, Del Gaudio M, Ravaioli M, Cescon M, Nannini M. Living donor liver transplantation for imatinib-resistant gastrointestinal stromal tumor liver metastases. A New Therapeutic Option in Transplant Oncology [Internet]. vol. 26, 2020, Liver Transplantation. John Wiley and Sons Ltd, [cited 2020 Dec 8]. pp. 1373–4. Available from: https://pubmed.ncbi.nlm.nih.gov/32640067/.
Ibrahim A, Chopra S. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. Arch Pathol Lab Med [Internet] 2020 May 1. [cited 2020 Dec 8];144(5):655–60. Available from. https://pubmed.ncbi.nlm.nih.gov/31169996/.
Neppala P, Banerjee S, Fanta PT, Yerba M, Porras KA, Burgoyne AM, et al. Current Management of Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumors. [Internet], Cancer and Metastasis Reviews. vol. 38, 2019, Springer, [cited 2020 Dec 8]. pp. 525–35. Available from: https://pubmed.ncbi.nlm.nih.gov/31773431/.
Rubió-Casadevall J, Martinez-Trufero J, Garcia-Albeniz X, Calabuig S, Lopez-Pousa A, del Muro JG, et al. Role of Surgery in Patients with Recurrent, Metastatic, or Unresectable Locally Advanced Gastrointestinal Stromal Tumors Sensitive to Imatinib: A Retrospective Analysis of the Spanish Group for Research on Sarcoma (GEIS). Ann Surg Oncol [Internet], 2015 Sep 12, [cited 2020 Dec 8];22(9):2948–57. Available from: https://pubmed.ncbi.nlm.nih.gov/25608769/.
Mehren M Von, Randall RL, Benjamin RS, Boles S, Bui MM, Ganjoo KN, et al. Soft Tissue Sarcoma. version 2.2018: Clinical practice guidelines in oncology [Internet], JNCCN Journal of the National Comprehensive Cancer Network. vol. 16, 2018, Harborside Press, [cited 2020 Dec 8]. pp. 536–63. Available from: https://pubmed.ncbi.nlm.nih.gov/29752328/.
Abreu P, Gorgen A, Oldani G, Hibi T, Sapisochin G. Recent Advances in Liver Transplantation for Cancer: the Future of Transplant Oncology. JHEP Reports [Internet]. 2019 Nov [cited 2020 Dec 8];1(5):377–91. Available from: https://pubmed.ncbi.nlm.nih.gov/32039389/.
Cascales-Campos PA, Ferreras D, Alconchel F, Febrero B, Royo-Villanova M, Martínez M, et al. Controlled Donation after Circulatory Death up to 80 Years for Liver Transplantation: Pushing the Limit Again. Am J Transplant [Internet. vol. 20(1): 2020 Jan 13, 204-212, Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-85070746057&partnerID=MN8TOARS.
Sapisochin G, Hibi T, Toso C, Man K, Berenguer M, Heimbach J, et al. Transplant Oncology in Primary and Metastatic Liver Tumors: Principles, Evidence, and Opportunities. vol. 273, 2021, Ann Surg [Internet, 483-493, Available from: http://www.ncbi.nlm.nih.gov/pubmed/33065633 . 3.
Demetri GD, Desai J, Fletcher JA, Morgan JA, Fletcher CDM, Kazanovicz A, et al. SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST). ASCO Annual Meeting. 2004, American Society of Clinical Oncology (ASCO), 3001–3001.
Atiq F, Broers AEC, Andrews LM, Doorduijn JK, Koch BCP, Van Gelder T, et al. A clinically relevant pharmacokinetic interaction between cyclosporine and imatinib. [Internet] Eur. J. Clin. Pharmacol. 2016. [cited 2020 Dec 8];72(6):719–23. Available from: https://pubmed.ncbi.nlm.nih.gov/26965514/.
Eskazan AE. Co-administration of cyclosporine A and imatinib among patients with Philadelphia chromosome-positive leukemias in the post-transplant setting [Internet]. European Journal of Clinical Pharmacology. vol. 72, 2016, Springer Verlag, [cited 2020 Dec 8]. pp. 1537–8. Available from: https://pubmed.ncbi.nlm.nih.gov/27558360/.
Cheung CY, Lo SHK, Chan CK, Li FK, Cheng IKP, Chau KF. Gastrointestinal stromal tumors in kidney transplant recipients: report of two cases and literature review. Asia Pac J Clin Oncol [Internet] 2017 Feb 1. [cited 2020 Dec 8];13(1):104–6. Available from. https://pubmed.ncbi.nlm.nih.gov/27461055/.
Seidel C, Fenner M, Länger F, Bantel H, Ganser A, Grünwald V. Imatinib-induced Liver Cirrhosis in a Patient with Advanced Gastrointestinal Stroma Tumor (GIST). BMC Cancer [Internet], 2012 May 21, [cited 2020 Dec 8];12. Available from: https://pubmed.ncbi.nlm.nih.gov/22612794/.
Nacif LS, Waisberg DR, Pinheiro RS, Lima FR, Rocha-Santos V, Andraus W, et al. Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report. [Internet] J. Med. Case Rep. 2018 Mar 10. [cited 2020 Dec 8];12(1). Available from. https://pubmed.ncbi.nlm.nih.gov/29523185/.
Duan Y, Haybaeck J, Yang Z. Therapeutic Potential of PI3K/AKT/mTor Pathway in Gastrointestinal Stromal Tumors: Rationale and Progress. Inside Internet. vol. 12, 2020, [cited 2020 Dec 8]. pp. 1–21. Available from: https://pubmed.ncbi.nlm.nih.gov/33066449/ . Cancers. MDPI AG.
Schnitzbauer AA, Filmann N, Adam R, Bachellier P, Bechstein WO, Becker T, et al. mTOR Inhibition Is Most Beneficial after Liver Transplantation for Hepatocellular Carcinoma in Patients with Active Tumors. Ann Surg [Internet], 2020 Nov 1, [cited 2020 Dec 8];272(5):855–62. Available from: https://pubmed.ncbi.nlm.nih.gov/32889867/.
De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R, et al. Use of Everolimus in Liver Transplantation: Recommendations from a Working Group [Internet]. vol. 101, 2017, Transplantation. Lippincott Williams and Wilkins, cited 2020 Dec 8]. pp. 239–51. Available from: https://pubmed.ncbi.nlm.nih.gov/27495768/.
Contributed Indexing:: Keywords: Gastrointestinal stromal tumor (GIST); Liver metastases; Liver neoplasms; Liver transplantation; Transplant oncology
Substance Nomenclature:: 0 (Antineoplastic Agents)
8A1O1M485B (Imatinib Mesylate)
Entry Date(s):: Date Created: 20210930 Date Completed: 20211111 Latest Revision: 20230302
Update Code:: 20240105
DOI:: 10.1016/j.ijsu.2021.106126
PMID:: 34592432
: Czasopismo naukowe

Full Text Finder

Background: Liver metastases from gastrointestinal stromal tumors (GIST) can be found synchronously to a primary tumor and in the medium/long term after resection of a high-risk GIST. In these cases, treatment with tyrosine kinase inhibitors like imatinib has provided good results, but drug resistance is common after two years of treatment. Liver resection of potentially resectable metastases can improve the results of medical treatment. In cases of unresectability, the role of liver transplantation (LT) has not been well-studied.
Materials and Methods: A review of the literature was undertaken from January 1995 to December 2020 following the PRISMA and AMSTAR guidelines.
Results: Fifteen cases were identified. In eight cases, the LT was carried out before 2002. Mutational status was only studied in seven cases. LT was performed in 12 cases with a deceased donor and in three cases with a living donor. After a mean follow-up of 52.4 months, overall survival was 86.6% with disease-free survival of 53.3% CONCLUSION: LT in the management of unresectable GIST metastases has rarely been performed. Although its application has a solid theoretical basis, its use understood as a radical extension of a standard resection can only be recommended within prospective studies by groups with considerable experience in both GIST and transplantation care.
(Copyright © 2021 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.)

Informacja